tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Larimar Therapeutics reports Q3 EPS (61c), consensus (42c)
PremiumThe FlyLarimar Therapeutics reports Q3 EPS (61c), consensus (42c)
2M ago
Larimar Therapeutics sees cash runway into 4Q26
Premium
The Fly
Larimar Therapeutics sees cash runway into 4Q26
2M ago
Larimar Therapeutics Advances Phase 1 Study on Nomlabofusp for Friedreich’s Ataxia
Premium
Company Announcements
Larimar Therapeutics Advances Phase 1 Study on Nomlabofusp for Friedreich’s Ataxia
2M ago
Citizens JMP healthcare analysts hold an analyst/industry conference call
PremiumThe FlyCitizens JMP healthcare analysts hold an analyst/industry conference call
3M ago
3 Best Stocks to Buy Now, 9/30/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 9/30/2025, According to Top Analysts
3M ago
Larimar Therapeutics price target lowered to $7 from $10 at Baird
Premium
The Fly
Larimar Therapeutics price target lowered to $7 from $10 at Baird
3M ago
Larimar announces 25 mg, 50 mg data from OL study of nomlabofusp
PremiumThe FlyLarimar announces 25 mg, 50 mg data from OL study of nomlabofusp
3M ago
Larimar Therapeutics provides updates on nomlabofusp program for FA
Premium
The Fly
Larimar Therapeutics provides updates on nomlabofusp program for FA
3M ago
Buy Rating for Larimar Therapeutics Driven by Positive Physician Sentiment and Promising Prospects for Nomlabofusp
Premium
Ratings
Buy Rating for Larimar Therapeutics Driven by Positive Physician Sentiment and Promising Prospects for Nomlabofusp
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100